e-Pharmatimes

GLP-1 Drugs in India: How Wegovy, Ozempic & Mounjaro Are Transforming the Weight-Loss Market GLP-1 Drugs in India: How Wegovy, Ozempic & Mounjaro Are Transforming the Weight-Loss Market in 2025 GLP-1 drugs like Wegovy, Ozempic, and Mounjaro are among the fastest-growing pharmaceutical products globally. In 2025, India is seeing a massive surge in awareness and demand for these advanced weight-loss and metabolic drugs. Major pharma companies, doctors, and investors agree that this category will reshape the future of chronic disease treatment. 🔥 Why GLP-1 Drugs Are Trending Worldwide They help with significant weight loss (10–20% body weight). Improve blood sugar control in Type 2 diabetes. Reduce cardiovascular risks. Early studies show liver benefits in fatty liver/MASH patients. Strong demand due to lifestyle diseases and obesity. 📌 What Are GLP-1 & Dual Agonist Drugs? GLP-1 (Glucagon-like peptide-1) agonists mimic a natural hormone that regulat...

Healthy Diet for Men Above 40 | Best Nutrition Guide for Men's Health Healthy Diet for Men Above 40: Complete Nutrition & Wellness Guide After 40, metabolism slows down, muscle mass declines, and the risk of diabetes, heart disease, and hormonal imbalance increases. A well-balanced diet plays a crucial role in preventing lifestyle disorders and maintaining long-term health. Recommended Reading: Learn how AI is transforming healthcare in our detailed post: AI in Healthcare & Pharma . Why Healthy Eating Becomes Essential After 40 Slower metabolism makes weight gain easier Muscle loss accelerates (sarcopenia) Increased risk of blood pressure & cholesterol Hormonal changes impact energy & mood Bone density gradually decreases Key Nutrients Every Man Above 40 Must Include Protein: Preserves muscle mass Omega-3 fatty acids: Heart & brain function Vitamin D + Calcium: Bone strength Magnesium: Reduces stress ...

Wegovy® (semaglutide 2.4 mg) Shows Liver Health Benefits in MASH Beyond Weight Loss Wegovy® (semaglutide 2.4 mg) Associated with Liver Health Benefits in MASH — Not Entirely Explained by Weight Loss Published: November 2025 | Category: Pharma & Hepatology Executive summary: A new post hoc analysis of the ESSENCE phase 3 program indicates that weekly semaglutide 2.4 mg (Wegovy®) was associated with improvements in liver inflammation, steatosis and fibrosis-related outcomes in adults with metabolic dysfunction–associated steatohepatitis (MASH) and liver scarring. Notably, a mediation analysis suggests these liver benefits are not explained solely by the magnitude of weight loss, implying potential weight-independent effects of semaglutide on liver health. [1][2] Key findings Semaglutide 2.4 mg recipients experienced greater improvement in liver injury (steatohepatitis) and liver-related non-invasive tests c...

Weight Loss Drugs and the Indian Pharmaceutical Economy: A New Era of Health and Business 💊 The New Revolution in Weight Loss: Beyond Diets and Gyms Weight management is no longer limited to gym routines and calorie counting. India’s healthcare landscape is witnessing a scientific revolution driven by advanced weight loss drugs such as semaglutide (Wegovy) and tirzepatide (Mounjaro) . These modern therapies are reshaping the country’s pharmaceutical economy, creating new business opportunities for both global and Indian companies. 🇮🇳 India’s Weight Loss Drug Boom in 2025 According to Reuters , India’s weight loss drug market crossed ₹600 crore in mid-2025 — a growth rate few other pharma categories can match. Global giants like Eli Lilly (Mounjaro) and Novo Nordisk (Wegovy) are driving the wave, while Indian companies such as Dr. Reddy’s, Lupin, Zydus, and Sun Pharma are fast-tracking their own anti-obesity formulations. For perspective, Mounjaro was launched ...

Koselugo (Selumetinib) Approved in the EU for Plexiform Neurofibromas in Adults with Neurofibromatosis Type 1 Published on: November 2025 | By: ePharma Times AstraZeneca and Merck & Co., Inc. have announced that Koselugo (selumetinib) has been granted marketing authorization in the European Union for the treatment of adults with Neurofibromatosis Type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PNs). Why This Matters NF1 is a rare genetic condition affecting around 1 in 3,000 people worldwide. These tumors can cause pain, disfigurement, and neurological complications. This EU approval marks a critical advancement in targeted therapy options for NF1, expanding treatment accessibility for adult patients across Europe. Clinical and Patient Impact Clinical studies demonstrated that selumetinib led to meaningful tumor shrinkage and improved patient outcomes. By targeting the MEK pathway , Koselugo re...